Sign In
Buy IMNN
$2.10
-0.0400 (-1.87%)
At Close: Jun 03, 2026
Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript
03:40pm, Tuesday, 12'th May 2026
Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript
IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update
08:00am, Tuesday, 12'th May 2026
IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment i
IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
08:30am, Tuesday, 05'th May 2026
LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company w
Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript
03:42pm, Tuesday, 31'st Mar 2026
Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
08:00am, Tuesday, 31'st Mar 2026
IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clin
The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysis Patients tre
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
08:00am, Tuesday, 24'th Mar 2026
LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Comp
Imunon (IMNN) Projected to Post Quarterly Earnings on Thursday
02:02am, Thursday, 19'th Feb 2026
Imunon (NASDAQ: IMNN - Get Free Report) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Imunon to post earnings of ($1.54) per share for
Head-To-Head Analysis: Pharma Mar (OTCMKTS:PHMMF) vs. Imunon (NASDAQ:IMNN)
02:08am, Friday, 13'th Feb 2026
Imunon (NASDAQ: IMNN - Get Free Report) and Pharma Mar (OTCMKTS:PHMMF - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
08:05am, Thursday, 05'th Feb 2026
Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the c
Head to Head Review: Allogene Therapeutics (NASDAQ:ALLO) and Imunon (NASDAQ:IMNN)
01:54am, Sunday, 11'th Jan 2026
Imunon (NASDAQ: IMNN - Get Free Report) and Allogene Therapeutics (NASDAQ: ALLO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two bu
Imunon, Inc. (NASDAQ:IMNN) Receives $232.50 Average Price Target from Analysts
02:04am, Saturday, 10'th Jan 2026
Shares of Imunon, Inc. (NASDAQ: IMNN - Get Free Report) have earned a consensus rating of "Hold" from the five analysts that are currently covering the firm, MarketBeat.com reports. One equities resea
IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
08:30am, Tuesday, 30'th Dec 2025
LAWRENCEVILLE, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has ent
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026
11:10am, Monday, 29'th Dec 2025
Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001's Promise as a Potential Breakthrough Immunotherapy LAWRENCEVIL
Imunon (NASDAQ:IMNN) Stock Price Up 5.3% – Should You Buy?
02:09am, Thursday, 11'th Dec 2025
Imunon, Inc. (NASDAQ: IMNN - Get Free Report)'s share price shot up 5.3% on Wednesday. The stock traded as high as $4.35 and last traded at $4.18. 117,956 shares were traded during mid-day trading, an
